{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T10:03:09Z","timestamp":1648893789622},"reference-count":61,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gyn\u00e9cologie Obst\u00e9trique Fertilit\u00e9 &amp; S\u00e9nologie\u00a0"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.gofs.2016.12.010","type":"journal-article","created":{"date-parts":[[2017,2,3]],"date-time":"2017-02-03T20:19:41Z","timestamp":1486153181000},"page":"37-42","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Le syndrome des antiphospholipides obst\u00e9trical\u00a0: quelle est la place d\u2019un traitement compl\u00e9mentaire \u00e0 la combinaison aspirine et h\u00e9parine\u00a0?"],"prefix":"10.1016","volume":"45","author":[{"given":"A.","family":"Mekinian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Kayem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Carbillon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Abisror","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Josselin-Mahr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Bornes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Fain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.gofs.2016.12.010_bib0005","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.revmed.2012.01.003","article-title":"Pregnancy and antiphospholipid syndrome","volume":"33","author":"Costedoat-Chalumeau","year":"2012","journal-title":"Rev Med Interne"},{"issue":"1","key":"10.1016\/j.gofs.2016.12.010_bib0010","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.autrev.2014.08.040","article-title":"Obstetrical APS: is there a place for hydroxychloroquine to improve the pregnancy outcome?","volume":"14","author":"Mekinian","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.gofs.2016.12.010_bib0015","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"3","key":"10.1016\/j.gofs.2016.12.010_bib0020","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/acr.20098","article-title":"Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome","volume":"62","author":"Ruffatti","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"9","key":"10.1016\/j.gofs.2016.12.010_bib0025","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1093\/rheumatology\/ker139","article-title":"Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study","volume":"50","author":"Ruffatti","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.gofs.2016.12.010_bib0030","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1136\/annrheumdis-2011-201167","article-title":"European registry of babies born to mothers with antiphospholipid syndrome","volume":"72","author":"Mekinian","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.gofs.2016.12.010_bib0035","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jri.2012.02.004","article-title":"Outcomes and treatment of obstetrical antiphospholipid syndrome in women with low antiphospholipid antibody levels","volume":"94","author":"Mekinian","year":"2012","journal-title":"J Reprod Immunol"},{"issue":"5","key":"10.1016\/j.gofs.2016.12.010_bib0040","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.autrev.2014.12.010","article-title":"The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): a survey of 247\u00a0consecutive cases","volume":"14","author":"Alijotas-Reig","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1016\/j.gofs.2016.12.010_bib0045","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1182\/blood-2013-08-522623","article-title":"Comparative incidence of pregnancy outcomes in treated obstetric antiphospholipid syndrome: the NOH-APS observational study","volume":"123","author":"Bouvier","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.gofs.2016.12.010_bib0050","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/art.10187","article-title":"Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000\u00a0patients","volume":"46","author":"Cervera","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.gofs.2016.12.010_bib0055","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0049-0172(99)80029-8","article-title":"Clinical study and follow-up of 100\u00a0patients with the antiphospholipid syndrome","volume":"29","author":"Munoz-Rodriguez","year":"1999","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.gofs.2016.12.010_bib0060","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/nrrheum.2015.88","article-title":"Current treatment of antiphospholipid syndrome: lights and shadows","volume":"11","author":"Espinosa","year":"2015","journal-title":"Nat Rev Rheumatol"},{"issue":"9","key":"10.1016\/j.gofs.2016.12.010_bib0065","first-page":"1261","article-title":"Antiphospholipid syndrome","volume":"61","author":"Fain","year":"2011","journal-title":"Rev Prat"},{"issue":"7","key":"10.1016\/j.gofs.2016.12.010_bib0070","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1002\/art.34402","article-title":"Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies","volume":"64","author":"Lockshin","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.gofs.2016.12.010_bib0075","first-page":"446","article-title":"Mothers\u2019 antiphospholipid antibodies during pregnancy and the relation to offspring outcome","volume":"32","author":"Mekinian","year":"2014","journal-title":"Clin Exp Rheumatol"},{"issue":"8","key":"10.1016\/j.gofs.2016.12.010_bib0080","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1002\/art.39668","article-title":"Changes in antiphospholipid antibody titers during pregnancy: data from the PROMISSE study","volume":"68","author":"Yelnik","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.gofs.2016.12.010_bib0085","doi-asserted-by":"crossref","unstructured":"Ruffatti A, Salvan E, Del Ross T, et al. Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. A European multicentre retrospective study. Thromb Haemost;112(4):727\u201335.","DOI":"10.1160\/TH14-03-0191"},{"issue":"5","key":"10.1016\/j.gofs.2016.12.010_bib0090","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/0002-9378(92)91596-3","article-title":"Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment","volume":"166","author":"Cowchock","year":"1992","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.gofs.2016.12.010_bib0095","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/0002-9378(93)90410-K","article-title":"Comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody-positive obstetric patients","volume":"169","author":"Silver","year":"1993","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"10.1016\/j.gofs.2016.12.010_bib0100","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/S0002-9378(96)70610-5","article-title":"Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone","volume":"174","author":"Kutteh","year":"1996","journal-title":"Am J Obstet Gynecol"},{"issue":"7076","key":"10.1016\/j.gofs.2016.12.010_bib0105","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1136\/bmj.314.7076.253","article-title":"Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies)","volume":"314","author":"Rai","year":"1997","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.gofs.2016.12.010_bib0110","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1471-0528.1999.tb08208.x","article-title":"Pregnancy complications in women with recurrent miscarriage associated with antiphospholipid antibodies treated with low dose aspirin and heparin","volume":"106","author":"Backos","year":"1999","journal-title":"Br J Obstet Gynaecol"},{"issue":"3","key":"10.1016\/j.gofs.2016.12.010_bib0115","first-page":"408","article-title":"Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment","volume":"100","author":"Farquharson","year":"2002","journal-title":"Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.gofs.2016.12.010_bib0120","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3899\/jrheum.080763","article-title":"Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial","volume":"36","author":"Laskin","year":"2009","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.gofs.2016.12.010_bib0125","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1067\/mob.2000.106754","article-title":"Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial","volume":"183","author":"Pattison","year":"2000","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.gofs.2016.12.010_bib0130","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/0961203312465782","article-title":"Treatment of refractory obstetric antiphospholipid syndrome: the state of the art and new trends in the therapeutic management","volume":"22","author":"Alijotas-Reig","year":"2012","journal-title":"Lupus"},{"issue":"6","key":"10.1016\/j.gofs.2016.12.010_bib0135","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/annrheumdis-2013-204838","article-title":"Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000\u00a0patients","volume":"74","author":"Cervera","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.gofs.2016.12.010_bib0140","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.revmed.2005.10.014","article-title":"Preeclampsia and antiphospholipid syndrome. Uterine artery Doppler evaluation","volume":"27","author":"Carbillon","year":"2006","journal-title":"Rev Med Interne"},{"issue":"2","key":"10.1016\/j.gofs.2016.12.010_bib0145","doi-asserted-by":"crossref","first-page":"131","DOI":"10.7326\/L15-0499","article-title":"Predictors of pregnancy outcomes in patients with lupus","volume":"164","author":"Carbillon","year":"2016","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.gofs.2016.12.010_bib0150","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.semarthrit.2013.07.001","article-title":"Autism spectrum disorders in babies born to mothers with antiphospholipid syndrome","volume":"43","author":"Abisror","year":"2013","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.gofs.2016.12.010_bib0155","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1542\/peds.2014-1097","article-title":"Very low birth weight, infant growth, and autism-spectrum traits in adulthood","volume":"134","author":"Pyhala","year":"2014","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/j.gofs.2016.12.010_bib0160","doi-asserted-by":"crossref","first-page":"e817","DOI":"10.1542\/peds.2008-3582","article-title":"Can association between preterm birth and autism be explained by maternal or neonatal morbidity?","volume":"124","author":"Buchmayer","year":"2009","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/j.gofs.2016.12.010_bib0165","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1542\/peds.2010-2846","article-title":"Prevalence of autism spectrum disorder in adolescents born weighing<2000\u00a0grams","volume":"128","author":"Pinto-Martin","year":"2011","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.gofs.2016.12.010_bib0170","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/aji.12493","article-title":"Unexplained recurrent miscarriage and recurrent implantation failure: is there a place for immunomodulation?","volume":"76","author":"Mekinian","year":"2016","journal-title":"Am J Reprod Immunol"},{"issue":"1","key":"10.1016\/j.gofs.2016.12.010_bib0175","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3109\/08916934.2014.939267","article-title":"Chronic histiocytic intervillositis: outcome, associated diseases and treatment in a multicenter prospective study","volume":"48","author":"Mekinian","year":"2015","journal-title":"Autoimmunity"},{"issue":"2","key":"10.1016\/j.gofs.2016.12.010_bib0180","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.placenta.2010.11.021","article-title":"Chronic histiocytic intervillositis of unknown etiology: clinical features in a consecutive series of 69\u00a0cases","volume":"32","author":"Marchaudon","year":"2011","journal-title":"Placenta"},{"issue":"1","key":"10.1016\/j.gofs.2016.12.010_bib0185","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/0961203312465782","article-title":"Treatment of refractory obstetric antiphospholipid syndrome: the state of the art and new trends in the therapeutic management","volume":"22","author":"Alijotas-Reig","year":"2013","journal-title":"Lupus"},{"issue":"25","key":"10.1016\/j.gofs.2016.12.010_bib0190","doi-asserted-by":"crossref","first-page":"6948","DOI":"10.1182\/blood-2011-02-339234","article-title":"First-trimester low-dose prednisolone in refractory antiphospholipid antibody-related pregnancy loss","volume":"117","author":"Bramham","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.gofs.2016.12.010_bib0195","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3892\/etm.2012.743","article-title":"Effect of prednisone, aspirin, low molecular weight heparin and intravenous immunoglobulin on outcome of pregnancy in women with antiphospholipid syndrome","volume":"5","author":"Xiao","year":"2011","journal-title":"Exp Ther Med"},{"issue":"6","key":"10.1016\/j.gofs.2016.12.010_bib0200","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.autrev.2015.01.012","article-title":"The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: data from a European multicenter retrospective study","volume":"14","author":"Mekinian","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.gofs.2016.12.010_bib0205","doi-asserted-by":"crossref","first-page":"273e1","DOI":"10.1016\/j.ajog.2015.09.078","article-title":"The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies","volume":"214","author":"Sciascia","year":"2016","journal-title":"Am J Obstet Gynecol"},{"issue":"1\u00a0Pt 1","key":"10.1016\/j.gofs.2016.12.010_bib0210","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S0002-9378(00)70500-X","article-title":"A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy","volume":"182","author":"Branch","year":"2000","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.gofs.2016.12.010_bib0215","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/art.10957","article-title":"Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies","volume":"48","author":"Triolo","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.gofs.2016.12.010_bib0220","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.autrev.2015.11.009","article-title":"Intravenous immunoglobulins and antiphospholipid syndrome: How, when and why? A review of the literature","volume":"15","author":"Tenti","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.gofs.2016.12.010_bib0225","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jri.2016.03.004","article-title":"Apheresis and intravenous immunoglobulins used in addition to conventional therapy to treat high-risk pregnant antiphospholipid antibody syndrome patients. A prospective study","volume":"115","author":"Ruffatti","year":"2016","journal-title":"J Reprod Immunol"},{"issue":"4","key":"10.1016\/j.gofs.2016.12.010_bib0230","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/jca.21229","article-title":"Plasma exchange and immunoadsorption effectively remove antiphospholipid antibodies in pregnant patients with antiphospholipid syndrome","volume":"27","author":"Bontadi","year":"2012","journal-title":"J Clin Apher"},{"issue":"3","key":"10.1016\/j.gofs.2016.12.010_bib0235","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.autrev.2006.11.002","article-title":"Plasma exchange in the management of high risk pregnant patients with primary antiphospholipid syndrome. A report of 9\u00a0cases and a review of the literature","volume":"6","author":"Ruffatti","year":"2007","journal-title":"Autoimmun Rev"},{"issue":"11","key":"10.1016\/j.gofs.2016.12.010_bib0240","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.autrev.2013.05.004","article-title":"Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab","volume":"12","author":"Berman","year":"2013","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.gofs.2016.12.010_bib0245","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/art.37759","article-title":"A pilot open-label phase\u00a0II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome","volume":"65","author":"Erkan","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.gofs.2016.12.010_bib0250","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/MD.0b013e318190f170","article-title":"A systematic review of the off-label use of biological therapies in systemic autoimmune diseases","volume":"87","author":"Ramos-Casals","year":"2008","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.gofs.2016.12.010_bib0255","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.lpm.2014.05.021","article-title":"Inefficacy of plasma exchanges associated to rituximab in refractory obstetrical antiphospholipid syndrome","volume":"44","author":"Abisror","year":"2015","journal-title":"Presse Med"},{"issue":"6","key":"10.1016\/j.gofs.2016.12.010_bib0260","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1136\/annrheumdis-2013-203622","article-title":"A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients","volume":"73","author":"Erkan","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.gofs.2016.12.010_bib0265","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1093\/humrep\/des288","article-title":"Pravastatin does not prevent antiphospholipid antibody-mediated changes in human first trimester trophoblast function","volume":"27","author":"Odiari","year":"2012","journal-title":"Hum Reprod"},{"issue":"5","key":"10.1016\/j.gofs.2016.12.010_bib0270","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1161\/HYPERTENSIONAHA.114.03115","article-title":"Clinical improvement and successful pregnancy in a preeclamptic patient with antiphospholipid syndrome treated with pravastatin","volume":"63","author":"Lefkou","year":"2014","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.gofs.2016.12.010_bib0275","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1161\/HYPERTENSIONAHA.115.05445","article-title":"Effects of pravastatin on human placenta, endothelium and women with severe preeclampsia","volume":"66","author":"Brownfoot","year":"2015","journal-title":"Hypertension"},{"issue":"2\u00a0Pt 1","key":"10.1016\/j.gofs.2016.12.010_bib0280","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/AOG.0b013e31827d8ad5","article-title":"Pravastatin for the prevention of preeclampsia in high-risk pregnant women","volume":"121","author":"Costantine","year":"2013","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.gofs.2016.12.010_bib0285","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.vph.2015.03.014","article-title":"Infliximab improves endothelial dysfunction in a mouse model of antiphospholipid syndrome: role of reduced oxidative stress","volume":"71","author":"Benhamou","year":"2015","journal-title":"Vascul Pharmacol"},{"issue":"8","key":"10.1016\/j.gofs.2016.12.010_bib0290","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1111\/ajt.12319","article-title":"Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes","volume":"13","author":"Canaud","year":"2013","journal-title":"Am J Transplant"},{"issue":"8","key":"10.1016\/j.gofs.2016.12.010_bib0295","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1002\/art.34440","article-title":"Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab","volume":"64","author":"Shapira","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.gofs.2016.12.010_bib0300","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1177\/0961203310389099","article-title":"Eculizumab and renal transplantation in a patient with catastrophic antiphospholipid syndrome: effect of heparin on complement activation","volume":"20","author":"Velik-Salchner","year":"2011","journal-title":"Lupus"},{"issue":"11","key":"10.1016\/j.gofs.2016.12.010_bib0305","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1093\/humrep\/17.11.2981","article-title":"Antiphospholipid antibodies (APA) and recurrent pregnancy loss: treating a unique APA positive population","volume":"17","author":"Franklin","year":"2002","journal-title":"Hum Reprod"}],"container-title":["Gyn\u00e9cologie Obst\u00e9trique Fertilit\u00e9 &amp; S\u00e9nologie\u00a0"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468718916300101?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468718916300101?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T22:00:56Z","timestamp":1636236056000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468718916300101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S2468718916300101"],"URL":"https:\/\/doi.org\/10.1016\/j.gofs.2016.12.010","relation":{},"ISSN":["2468-7189"],"issn-type":[{"value":"2468-7189","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Le syndrome des antiphospholipides obst\u00e9trical\u00a0: quelle est la place d\u2019un traitement compl\u00e9mentaire \u00e0 la combinaison aspirine et h\u00e9parine\u00a0?","name":"articletitle","label":"Article Title"},{"value":"Gyn\u00e9cologie Obst\u00e9trique Fertilit\u00e9 & S\u00e9nologie\u00a0","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gofs.2016.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}